http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#Head http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#assertion http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#provenance http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#pubinfo http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#assertion http://purl.obolibrary.org/obo/DOID_3908 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3908 http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00441 http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association http://www.w3.org/2000/01/rdf-schema#label gemcitabine for injection is a nucleoside metabolic inhibitor indicated in combination with carboplatin for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum based therapy 1 1 in combination with paclitaxel for first line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy unless anthracyclines were clinically contraindicated 1 2 in combination with cisplatin for the treatment of non small cell lung cancer 1 3 as a single agent for the treatment of pancreatic cancer 1 4 gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum based therapy gemcitabine for injection in combination with paclitaxel is indicated for the first line treatment of patients with metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy unless anthracyclines were clinically contraindicated gemcitabine for injection is indicated in combination with cisplatin for the first line treatment of patients with inoperable locally advanced stage iiia or iiib or metastatic stage iv non small cell lung cancer gemcitabine for injection is indicated as first line treatment for patients with locally advanced nonresectable stage ii or stage iii or metastatic stage iv adenocarcinoma of the pancreas gemcitabine for injection is indicated for patients previously treated with 5 fu http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00441 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#provenance http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#pubinfo http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#sig http://purl.org/nanopub/x/hasSignature LpEG6isIg/dD5Ab1zD+u5vKd9auQnpW1umKYR3A6qXr7XDnXCLX2JTpWtWJTH8QxqRCCmH9iMAUqWKzyQ92grBg1rzxecGCTKOYo4EV62kDajoXVXsfC7DFcAl6MM9aL5eb6pEWKbzmYa53l4lwTU54XxPUIq2VfPkWqgj000vY= http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM http://purl.org/dc/terms/created 2021-06-15T17:51:32.201+02:00 http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs